2024-05-01 06:30 | UU:JNJ | | News Release200 | Johnson & Johnson Announces Plan by its Subsidiary, LLT Management LLC, to Resolve All Current and Future Ovarian Cancer Talc Claims Through a Consensual "Prepackaged" Reorganization |
2024-04-22 16:30 | UU:JNJ | | News Release200 | Johnson & Johnson to Participate in the Bernstein's 40th Annual Strategic Decisions Conference (SDC) |
2024-04-20 01:28 | UU:JNJ | | SEDAR Annual Report803 | SEDAR MD & A |
2024-04-16 06:25 | UU:JNJ | | News Release200 | Johnson & Johnson Announces 62nd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.2% |
2024-04-16 03:20 | UU:JNJ | | News Release200 | CORRECTING and REPLACING Johnson & Johnson Reports Q1 2024 Results |
2024-04-08 18:06 | UU:JNJ | | News Release200 | Johnson & Johnson to Participate in the 2024 RBC Capital Markets Global Healthcare Conference |
2024-04-05 23:21 | UU:JNJ | | News Release200 | CARVYKTI(TM) is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy |
2024-04-05 06:31 | UU:JNJ | | News Release200 | Johnson & Johnson to Acquire Shockwave Medical |
2024-04-04 18:01 | UU:JNJ | | News Release200 | Johnson & Johnson Recommends Shareholders Reject "Mini-Tender" Offer by TRC Capital Investment Corporation |
2024-04-02 16:30 | UU:JNJ | | News Release200 | Johnson & Johnson to Participate in the BofA Securities Health Care Conference |
2024-03-12 09:15 | UU:JNJ | | News Release200 | Artelo Biosciences Selected as a Finalist in Johnson & Johnson's Innovation Challenge |
2024-03-11 16:30 | UU:JNJ | | News Release200 | Johnson & Johnson to Host Investor Conference Call on First-Quarter Results |
2024-03-07 08:33 | UU:JNJ | | News Release200 | Johnson & Johnson Completes Acquisition of Ambrx |
2024-03-01 15:59 | UU:JNJ | | News Release200 | RYBREVANT(TM) (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations |
2024-02-20 16:26 | UU:JNJ | | News Release200 | TECVAYLI ‚ ® (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with relapsed or refractory multiple myeloma |
2024-02-14 16:30 | UU:JNJ | | News Release200 | Johnson & Johnson to Participate in the Barclays 26th Annual Global Healthcare Conference |
2024-02-12 16:10 | UU:JNJ | | News Release200 | Johnson & Johnson to Participate in the Leerink Global Biopharma Conference |
2024-02-02 16:10 | UU:JNJ | | News Release200 | Johnson & Johnson to Participate in the Raymond James 45th Annual Institutional Investors Conference |
2024-01-24 15:42 | UU:JNJ | | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
2024-01-23 06:20 | UU:JNJ | | News Release200 | Johnson & Johnson Reports Q4 and Full-Year 2023 Results |
2024-01-08 07:30 | UU:JNJ | | News Release200 | Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer |
2024-01-02 08:00 | UU:JNJ | | News Release200 | Johnson & Johnson Announces Quarterly Dividend for First Quarter 2024 |
2023-12-19 12:05 | UU:JNJ | | SEDAR Interim MD & A813 | SEDAR Interim MD & A |
2023-12-12 11:40 | UU:JNJ | | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
2023-12-11 16:15 | UU:JNJ | | News Release200 | Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results |
2023-12-07 16:15 | UU:JNJ | | News Release200 | Johnson & Johnson to Participate in the 42nd Annual J.P. Morgan Healthcare Conference |
2023-12-07 13:31 | UU:JNJ | | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
2023-12-05 07:15 | UU:JNJ | | News Release200 | Johnson & Johnson Announces Key Drivers for Long-Term Competitive Growth at Enterprise Business Review |
2023-11-30 16:30 | UU:JNJ | | News Release200 | Johnson & Johnson Names Eugene A. Woods, Chief Executive Officer of Advocate Health, to its Board of Directors |
2023-11-30 08:40 | UU:JNJ | | News Release200 | Johnson & Johnson MedTech Acquires Laminar, Inc. |
2023-11-16 07:30 | UU:JNJ | | News Release200 | Johnson & Johnson to Host Enterprise Business Review |
2023-10-23 16:15 | UU:JNJ | | News Release200 | Johnson & Johnson Announces Departure of Ashley McEvoy, Tim Schmid Named Executive Vice President, Worldwide Chairman of MedTech |
2023-10-19 13:43 | UU:JNJ | | News Release200 | Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2023 |
2023-10-17 06:20 | UU:JNJ | | News Release200 | Johnson & Johnson Reports Q3 2023 Results |
2023-09-18 16:30 | UU:JNJ | | News Release200 | Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results |
2023-09-14 10:00 | UU:JNJ | | News Release200 | Johnson & Johnson Marks New Era as Global Healthcare Company With Updated Visual Identity |
2023-08-30 06:30 | UU:JNJ | | News Release200 | Johnson & Johnson Announces Updated Financials and 2023 Guidance Following Completion of the Kenvue Separation |
2023-08-23 06:20 | UU:JNJ | | News Release200 | Johnson & Johnson Announces Final Results of Exchange Offer and Finalizes Separation of Kenvue Inc. |
2023-08-22 10:24 | UU:JNJ | | News Release200 | Johnson & Johnson to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference |
2023-08-21 18:01 | UU:JNJ | | News Release200 | Kenvue Set to Join S&P 500; Advance Auto Parts to Join S&P SmallCap 600 |
2023-08-21 06:20 | UU:JNJ | | News Release200 | Johnson & Johnson Announces Preliminary Results of Kenvue Inc. Exchange Offer |
2023-08-16 18:52 | UU:JNJ | | News Release200 | Johnson & Johnson Announces Final Exchange Ratio of 8.0324 in Split-Off of Kenvue Inc. |
2023-08-10 18:58 | UU:JNJ | | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
2023-08-09 18:58 | UU:JNJ | | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
2023-08-09 18:42 | UU:JNJ | | News Release200 | Kenvue Set to Join S&P 500 |
2023-08-08 18:58 | UU:JNJ | | SEDAR Interim Financial Statements812 | SEDAR Interim Financial Statements |
2023-08-07 19:29 | UU:JNJ | | News Release200 | Johnson & Johnson to Participate in the 2023 Wells Fargo Securities Healthcare Conference |
2023-07-24 06:22 | UU:JNJ | | News Release200 | Kenvue To File Form S-4 Registration Statement in Connection with Johnson & Johnson Exchange Offer Announcement |
2023-07-24 06:18 | UU:JNJ | | News Release200 | Johnson & Johnson Launches Exchange Offer for Separation of Kenvue Inc. |
2023-07-20 06:20 | UU:JNJ | | News Release200 | Johnson & Johnson Reports Q2 2023 Results |
2023-07-10 16:30 | UU:JNJ | | News Release200 | Johnson & Johnson to Participate in the UBS MedTech, Tools and Genomics Summit |
2023-06-12 03:00 | UU:JNJ | | News Release200 | Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara ‚ ® |
2023-06-06 16:30 | UU:JNJ | | News Release200 | Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results |
2023-05-10 16:30 | UU:JNJ | | News Release200 | Johnson & Johnson to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference |